Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
November 20, 2023 01:00 ET
|
Oxurion NV
Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 19, 2023 15:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year
November 16, 2023 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies,...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 16, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
November 15, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – November 15, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 06, 2023 14:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
November 03, 2023 15:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
October 30, 2023 03:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial
October 25, 2023 02:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
October 20, 2023 14:01 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...